GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Inventories, Raw Materials & Components

EGEIRO Pharma (XPAR:ALVET) Inventories, Raw Materials & Components : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EGEIRO Pharma Inventories, Raw Materials & Components?

EGEIRO Pharma's inventories, raw materials & components for the quarter that ended in Dec. 2023 was €0.00 Mil.

EGEIRO Pharma's annual raw materials declined from Dec. 2021 (€0.03 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


EGEIRO Pharma Inventories, Raw Materials & Components Historical Data

The historical data trend for EGEIRO Pharma's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EGEIRO Pharma Inventories, Raw Materials & Components Chart

EGEIRO Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - 0.03 - -

EGEIRO Pharma Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EGEIRO Pharma Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


EGEIRO Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
N/A
Address
Avenue Jean Mermoz 32/1, Gosselies, BEL, 6041
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.

EGEIRO Pharma Headlines

No Headlines